Skip to main content

Table 3 Utilization of medical care by participants with migraine (N = 3466)

From: Poor medical care for people with migraine in Europe – evidence from the Eurolight study

Country

N

Using triptans (of all with migraine) n (%)

Migraine on ≥5 days/month n (%)

Using preventative medication (of those with migraine on ≥5 days/month) n (%)

Consulting health professionals n (%)

Specialist

General practitioner

Non-medical

None

Studies with a general-population basis

Germany

109

12 (11.0)

42 (38.5)

1 (2.4)

7 (6.4)

14 (12.8)

5 (4.6)

83 (76.1)

Italy

221

14 (6.3)

61 (27.6)

1 (1.6)

14 (6.3)

21 (9.5)

15 (6.8)

171 (77.4)

Lithuania

149

5 (3.4)

62 (41.6)

2 (3.2)

16 (10.7)

23 (15.4)

2 (1.3)

108 (72.5)

Luxemburg

669

48 (7.2)

219 (32.7)

10 (4.6)

39 (5.8)

105 (15.7)

27 (4.0)

498 (74.4)

Netherlands-population

815

75 (9.2)

171 (20.8)

11 (6.4)

25 (3.1)

106 (13.0)

36 (4.4)

648 (79.5)

Spain-workplace

401

90 (22.4)

153 (38.2)

21 (13.7)

60 (15.0)

72 (18.0)

28 (7.0)

241 (60.1)

Studies conducted in general practice settings

Austria

263

37 (14.1)

106 (40.3)

7 (6.6)

46 (17.5)

26 (10.0)

14 (5.3)

177 (67.3)

France

337

46 (13.6)

91 (27.0)

4 (4.4)

7 (2.1)

81 (24.0)

22 (6.5)

227 (67.3)

UK

49

12 (24.5)

22 (44.9)

2 (9.1)

11 (22.4)

7 (14.3)

0 (0)

31 (63.3)

Studies among members of lay headache organizations

Ireland

152

94 (61.8)

78 (51.3)

23 (29.5)

34 (22.4)

45 (29.6)

6 (3.9)

67 (44.1)

Netherlands-lay

195

133 (68.2)

120 (61.5)

50 (41.7)

66 (33.8)

26 (13.3)

21 (11.0)

82 (42.1)

Spain-lay

106

49 (46.2)

50 (47.2)

8 (16.0)

25 (23.6)

27 (25.5)

10 (9.4)

44 (41.5)